Nilüfer Çakır-Özkan1, Sinan Eğri2, Esengül Bekar3, B Zuhal Altunkaynak4, Yonca Betil Kabak5, Elfide Gizem Kıvrak6. 1. Associate Professor, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Ondokuz Mayis University, Samsun, Turkey. Electronic address: nfozkan@hotmail.com. 2. Assistant Professor, Department of Bioengineering, Faculty of Engineering and Natural Sciences, Gaziosmanpaşa University, Tokat, Turkey. 3. Assistant Professor, Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Gaziosmanpaşa University, Tokat, Turkey. 4. Associate Professor, Department of Histology and Embryology, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Turkey. 5. Assistant Professor, Department of Pathology, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey. 6. Research Assistant, Department of Histology and Embryology, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey.
Abstract
PURPOSE: Promising developments have materialized in reconstructive surgical procedures with the applications of tissue engineering. In our study, we used tissue scaffolds fabricated from polylactic acid-polyethylene glycol (PLLA-PEG) copolymers to ensure different release rates of selective growth factors recombinant human bone morphogenetic protein 2 [rhBMP-2] and vascular endothelial growth factor (rhVEGF165) in the repair of mandibular bone defects. MATERIALS AND METHODS: In our experimental study, 54 New Zealand rabbits were used. The rabbits were separated into 4 groups: group I (control group), PLLA-PEG scaffold only; group II, PLLA-PEG scaffold plus rhBMP-2 application; group III, PLLA-PEG scaffold plus VEGF165 application; and group IV, PLLA-PEG scaffold plus rhBMP-2 and VEGF165 applications. The rabbits were killed at 4 and 8 weeks postoperatively, and histopathologic and immunohistochemical assessments were performed. RESULTS: The greatest bone volume was observed in rhBMP-2-containing groups, the greatest vessel volume was observed in VEGF165-containing groups; however, the scaffold containing rhBMP-2 and VEGF165 provided the best outcomes in conjunction with increased remodeling of the new bone. CONCLUSIONS: The use of polymer tissue scaffolds that release rhVEGF165 and rhBMP-2 in coordination and mimic the natural healing process in the regeneration of especially complex tissues, such as bone, is a promising treatment alternative in the field of reconstructive surgery.
PURPOSE: Promising developments have materialized in reconstructive surgical procedures with the applications of tissue engineering. In our study, we used tissue scaffolds fabricated from polylactic acid-polyethylene glycol (PLLA-PEG) copolymers to ensure different release rates of selective growth factors recombinant humanbone morphogenetic protein 2 [rhBMP-2] and vascular endothelial growth factor (rhVEGF165) in the repair of mandibular bone defects. MATERIALS AND METHODS: In our experimental study, 54 New Zealand rabbits were used. The rabbits were separated into 4 groups: group I (control group), PLLA-PEG scaffold only; group II, PLLA-PEG scaffold plus rhBMP-2 application; group III, PLLA-PEG scaffold plus VEGF165 application; and group IV, PLLA-PEG scaffold plus rhBMP-2 and VEGF165 applications. The rabbits were killed at 4 and 8 weeks postoperatively, and histopathologic and immunohistochemical assessments were performed. RESULTS: The greatest bone volume was observed in rhBMP-2-containing groups, the greatest vessel volume was observed in VEGF165-containing groups; however, the scaffold containing rhBMP-2 and VEGF165 provided the best outcomes in conjunction with increased remodeling of the new bone. CONCLUSIONS: The use of polymer tissue scaffolds that release rhVEGF165 and rhBMP-2 in coordination and mimic the natural healing process in the regeneration of especially complex tissues, such as bone, is a promising treatment alternative in the field of reconstructive surgery.
Authors: M Orth; T Fritz; J Stutz; C Scheuer; B Ganse; Y Bullinger; J S Lee; W L Murphy; M W Laschke; M D Menger; T Pohlemann Journal: Front Bioeng Biotechnol Date: 2022-01-11